Residual cell content in plasma produced by three centrifugal apheresis procedures

Transfusion

Volumn 43, Issue 11, 2003, Pages 1522-1526

  Burnouf, Thierry ^a   Kappelsberger, Claudia ^a   Frank, Kerstin ^a   Burkhardt, Thomas ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

APHERESIS; ARTICLE; BLOOD DONOR; BLOOD TRANSFUSION; CENTRIFUGATION; DEVICE; ERYTHROCYTE COUNT; HEMOGLOBIN ANALYSIS; HUMAN; HUMAN CELL; LEUKOCYTE COUNT; PARTIAL THROMBOPLASTIN TIME; PLASMA; SEPARATION TECHNIQUE;

BLOOD CELL COUNT; BLOOD COMPONENT REMOVAL; CENTRIFUGATION; ERYTHROCYTE COUNT; HUMANS; LEUKOCYTE COUNT; PLASMA; PLATELET COUNT; PROSPECTIVE STUDIES; RANDOM ALLOCATION;

EID: 0242440046     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.2003.00543.x     Document Type: Article

References (29)

1. Guidelines for the blood transfusion services of the United Kingdom. 6th ed. Norwich: The Stationery Office; 2002.
2. Richtlinien zur Gewinnung von Blut und Blutbestandteilen und zur Anwendung von Blutprodukten (Hämotherapie). Bundesgesundheitsbl Gesundheltsforsch Gesundheitsschutz 2000;43:555-89.
3. Guide to the preparation, use, and quality assurance of blood components. 8th ed. Strasbourg: Council of Europe Publishing, 2002.
4. Analyse du risque de transmission de la variante de la maladie de Creutzfeldt-Jakob par les médicaments d'origine humaine et par les produits sanguins labiles - Actualisation des données du rapport du groupe ad hoc de décembre 2000. Rapport. Saint Denis: AFSSAPS; 2003 Mar:1-22.
5. Burnouf T, Kappelsberger C, Frank K, Burkhardt T. Protein composition and activation markers in plasma collected by three apheresis procedures. Transfusion 2003;43:1223-30.
6. Rapoport S, Raderecht. H. Physiologisch-chemisches praktikum. Berlin: Verlag Volk und Gesundheit; 1984:337.
7. Vrielink H. Leukodepleted apheresis plasma without a filter. Vox Sang 2002;83:222.
8. Zingsem J, Weisbach V, Zimmermann R, et al. Preparation of FFP as a by-product of plateletpheresis. Transfusion 2002;42:81-6.
9. Hiruma K, Okuyama Y. Effect of leucocyte reduction on the potential alloimmunogenicity of leucocytes in fresh-frozen plasma products. Vox Sang 2001;80:51-6.
10. Bernvil SS, Abdulatiff M, al-Sedairy S, et al. Fresh frozen plasma contains viable progenitor cells - should we irradiate? Vox Sang 1994;67:405.
11. Wieding JU, Vehmeyer K, Dittman J, et al. Contamination of fresh-frozen plasma with viable white cells and proliferable stem cells. Transfusion 1994;34:185-6.
12. Hurtado C, Bonanad S, Soler M, et al. Quality analysis of blood components obtained by automated buffy-coat layer removal with a top & bottom system (Optipress (R) II). Haematologica 2000;85:390-5.
13. Isbister JP. Adverse reactions to plasma and plasma components. Anaesthes Intens Care 1993;21:31-8.
14. Nielsen H, Pedersen A, Dybkjoer E, et al. Leucocyte-derived bioactive substances in fresh frozen plasma. Br J Anaesth 1997;78:548-52.
15. Smith JK. Quality of plasma for fractionation - does it matter? Transfus Sci 1994;15:343-50.
16. Cohn E, Strong L, Hughes W, et al. Preparation and properties of serum and plasma proteins. IV. A system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. J Am Chem Soc 1946;68:459-75.
17. Burnouf T, Radosevich M. Affinity chromatography in the industrial purification of plasma proteins for therapeutic use. J Biochem Biophys Methods 2001;49:575-86.
18. Wadhwa M, Dilger P, Tubbs J, et al. Identification of transforming growth factor-beta as a contaminant in factor VIII concentrates: a possible link with immunosuppressive effects in hemophiliacs. Blood 1994;84:2021-30.
19. Hodge G, Han P. Effect of intermediate-purity factor VIII (FVIII) concentrate on lymphocyte proliferation and apoptosis: transforming growth factor-beta is a significant immunomodulatory component of FVIII. Br J Haematol 2001;115:376-81.
20. Burnouf T, Burnouf-Radosevich M, Huart JJ, Goudemand M. A highly purified factor VIII:c concentrate prepared from cryoprecipitate by ion-exchange chromatography. Vox Sang 1991;60:8-15.
21. Mannuccio PM, Lattuada A, Ruggeri ZM. Proteolysis of von Willebrand factor in therapeutic plasma concentrates. Blood 1994;83:3018-27.
22. Burnouf T, Radosevich M. Reducing the risk of infection from plasma products: specific preventative strategies. Blood Rev 2000;14:94-110.
23. Turner M, Ironside J. New-variant Creutzfeldt-Jakob disease: the risk of transmission by blood transfusion. Blood Rev 1998;12:255-68.
24. Brown P, Cervenakova L, McShane L, et al. Further studies of blood infectivity in an experimental model of transmissible spongiform encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt-Jakob disease in humans. Transfusion 1999;39:1169-78.
25. Karger R, Kretschmer V. Inline-filtration. Transfus Apheresis Sci 2002;27:137-52.
26. Foster PR, Welch AG, McLean C, et al. Studies on the removal of abnormal prion protein by processes used in the manufacture of human plasma products. Vox Sang 2000;78: 86-95.
27. Stenland CJ, Lee DC, Brown P, et al. Partitioning of human and sheep forms of the pathogenic prion protein during the purification of therapeutic proteins from human plasma. Transfusion 2002;42:1497-500.
28. Sonntag J, Emeis M, Vornwald A, et al. Complement activation during plasma production depends on the apheresis technique. Transfus Med 1998;8:205-8.
29. Sonntag J, Stiller B, Walka MM, Maier RF. Anaphylatoxins in fresh-frozen plasma. Transfusion 1997;37:798-803.